Dec 22, 2025
Adeia Strikes Long-Term Disney Deal, Ends Legal Fight, Lifts Outlook

Adeia Inc. (NASDAQ:ADEA) announced Monday that it has finalized a long-term licensing arrangement with The Walt Disney Company (NYSE:DIS), bringing an end to all pending legal disputes between the two companies. The stock soared post the announcement. The deal grants…

Dec 22, 2025
Insights Into Oracle’s Performance Versus Peers In Software Sector

Amidst the fast-paced and highly competitive business environment of today, conducting comprehensive company analysis is essential for investors and industry enthusiasts. In this article, we will delve into an extensive industry comparison, evaluating Oracle (NYSE:ORCL) in comparison to its major…

Dec 22, 2025
Price Over Earnings Overview: Affiliated Managers Group

In the current session, the stock is trading at $281.79, after a 0.97% increase. Over the past month, Affiliated Managers Group Inc. (NYSE:AMG) stock increased by 5.89%, and in the past year, by 50.30%. With performance like this, long-term shareholders…

Dec 22, 2025
CACI Moves Into Space-Based Intelligence With $2.6B ARKA Deal

CACI International, Inc. (NYSE:CACI) shares are trading higher on Monday after the company disclosed an agreement to acquire ARKA Group L.P. (ARKA) from Blackstone Tactical Opportunities. The all-cash deal is valued at $2.6 billion. ARKA's space-based sensors and ground software capabilities…

Dec 22, 2025
This Cummins Analyst Turns Bullish; Here Are Top 2 Upgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Loop Capital analyst Anthony Chukumba upgraded Ollie’s Bargain Outlet…

Dec 22, 2025
FDA Flags Deadly Risks, AstraZeneca Pulls Andexxa From US Market

The U.S. Food and Drug Administration (FDA) said the safety risks associated with Andexxa now outweigh its benefits, prompting AstraZeneca Plc (NASDAQ:AZN) to seek a voluntary withdrawal of the drug’s biologics license and plan an exit from the U.S. market.…